Close
  Indian J Med Microbiol
 

Figure 1: Potential targeted therapy, including potential natural small compounds, for triple-negative breast cancer. cancer stem cells, epithelial-mesenchymal transition, cell proliferation, and evasion of growth suppression lead to triple-negative breast cancer cell heterogeneity. Neovascularization through angiogenesis and immune cell suppression create a protumorigenic tumor microenvironment. Crosstalk between cancer cells and the tumor microenvironment are required for tumor initiation, progression, drug resistance, relapse, as well as distant metastasis. Herein, we highlight several oncogenes (red) and one tumor suppressor gene (blue) that regulate cancer cell heterogeneity as well as the tumor microenvironment as a potential new approach to triple-negative breast cancer treatment. On the basis of our previously study, ovatodiolide, pterostilbene, and antrocin are potential natural small compounds with anticancer properties against triple-negative breast cancer, achieved through targeting cancer cells and the tumor microenvironment

Figure 1: Potential targeted therapy, including potential natural small compounds, for triple-negative breast cancer. cancer stem cells, epithelial-mesenchymal transition, cell proliferation, and evasion of growth suppression lead to triple-negative breast cancer cell heterogeneity. Neovascularization through angiogenesis and immune cell suppression create a protumorigenic tumor microenvironment. Crosstalk between cancer cells and the tumor microenvironment are required for tumor initiation, progression, drug resistance, relapse, as well as distant metastasis. Herein, we highlight several oncogenes (red) and one tumor suppressor gene (blue) that regulate cancer cell heterogeneity as well as the tumor microenvironment as a potential new approach to triple-negative breast cancer treatment. On the basis of our previously study, ovatodiolide, pterostilbene, and antrocin are potential natural small compounds with anticancer properties against triple-negative breast cancer, achieved through targeting cancer cells and the tumor microenvironment